



Theradiag and Biogaran sign a partnership agreement

Lisa Tracker® monitoring tests to be offered with Biogaran's biosimilar drugs

Croissy-Beaubourg, March 28, 2018, 6:00pm CEST – THERADIAG (ISIN code: FR0004197747, Ticker: ALTER), a company specialized in *in vitro* diagnostics and theranostics, is today announcing that it has entered into a partnership agreement with pharma group Biogaran to supply its Lisa Tracker® kits for monitoring Biogaran's biosimilar drugs.

Under this agreement, Biogaran has referenced the Lisa Tracker® monitoring kits in France to support the biosimilar drugs it supplies. Theradiag will handle implementation, provide training to laboratories in how to use kits and follow up on clinician requests concerning monitoring.

Biogaran, a French pharmaceutical group specialized in generics, set itself the twin goal following its inception in 1996 of providing drugs that meet the needs of patients, pharmacists and doctors, and of promoting proper use of them. In 2014, it set up Biogaran Biosimilaires and then in February 2015 launched Remsima® (infliximab), the first anti-TNFα biosimilar in France, approved by the EMA (European Medicines Agency). Biogaran went on to become one of the leading players in complex biosimilars and the no. 2 ranked supplier of biosimilars to hospitals.

"It gives us great pleasure to combine Theradiag's know-how with our own areas of expertise", commented Daniel Roederer, Biogaran's Director of Operations.

"Together with our partnerships with Janssen, MSD, Pfizer and Biogen, this deal with Biogaran will enable us to supply our Lisa Tracker® kits with all the infliximabs on the market and also for other monoclonal antibodies. It's also very good news for doctors and their patients, as it will facilitate more personalized therapies", added Michel Finance, Theradiag's Chief Executive Officer.

Next Financial Press Release

2017 results and 2018 First-quarter sales: April 10, 2018

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



ALTER
EURONEXT
GROWTH



Theradiag

Investor Relations

Fabienne François

CFO

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Financial Communications
& Investor Relations

Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theradiag@newcap.eu

Alize RP

Press Relations

Caroline Carmagnol

Tel.: +33 (0)1 44 54 36 64

theradiag@alizerp.com